VMD55 Programme
VMD55 is Aedion's lead asset — a dengue antiviral programme held under a globally structured exclusive licence, advancing through a defined pathway — informed by a completed Phase III clinical trial in the predecessor compound, now preparing Phase 2a for VMD55.
Lead Asset
VMD55 is Aedion's lead asset, grounded in the pioneering scientific work of Professor Max Reynolds and held under a global exclusive licence and supply framework. Aedion is the single authoritative global holder of the programme — responsible for its development, protection, standardisation, and clinical advancement.
VMD55 builds on prior clinical work. In a randomised, double-blind, placebo-controlled Phase III trial in Indonesia, patients treated with MAC, the predecessor material to VMD55, cleared dengue virus significantly faster than placebo (p=0.013), and the material was well tolerated. Aedion is advancing VMD55 from that clinical observation under a globally structured development framework; demonstrating chemical continuity between VMD55 and the trial material is a programme objective.
| Asset | VMD55 |
| Primary Indication | Dengue |
| Future Expansion | Adjacent high-burden mosquito-borne viral diseases |
| Rights Structure | Global exclusive licence and supply framework — single global holder |
| Scientific Origin | Pioneering research programme of Professor Max Reynolds |
| Development Stage | Predecessor compound Ph III complete · VMD55 Phase 2a preparation underway · priority markets identified |
| IP Strategy | Active protection and strategic expansion of surrounding intellectual property |
| Quality Standard | GMP-aligned international quality development pathway |
| Regulatory Plan | Regulatory strategy mapped for priority dengue-endemic markets |
Clinical Evidence
The predecessor compound to VMD55 has already completed a Phase III clinical trial in Indonesia — giving the VMD55 programme a clinical starting point that a conventional early-stage asset does not have.
In a randomised, double-blind, placebo-controlled trial (532 randomised, ~450 analysed per protocol), patients treated with MAC cleared dengue virus significantly faster than placebo (p=0.013), with an accompanying immunomodulatory signal. The material was well tolerated across three human studies. The mechanism by which this occurs is not yet established: in-vitro work demonstrates direct virucidal activity, but only at concentrations far above those achievable by oral dosing, and a host-response mechanism remains a hypothesis. Establishing the mechanism, and demonstrating chemical continuity between the current material and the material used in 2013, are the two objectives of our current programme.
Phase III clinical trial conducted in Indonesia. Results pertain to the predecessor compound to VMD55 and do not constitute regulatory approval of VMD55. Aedion Therapeutics is advancing VMD55 through an independent development and regulatory pathway. Chemical continuity between VMD55 and the trial material has not yet been established.
Development Pathway
Aedion is advancing VMD55 through a rigorous, systematically planned development pathway appropriate for priority dengue-endemic markets and designed to maintain internationally credible regulatory standards throughout.
Development Mandate
Aedion was not created to start from zero. Its mandate is specific: to secure, protect, standardise, and advance an existing body of scientific work through the commercial, legal, and clinical infrastructure needed to make it a globally credible therapeutic asset.
Rights & IP Structure
Platform Potential
While Aedion's immediate focus is the disciplined development of VMD55 in dengue, the company is structured from the outset to become a broader platform in mosquito-borne and viral disease therapeutics.
The expertise, infrastructure, regulatory relationships, and scientific credibility built through the VMD55 programme create a natural foundation for expansion into adjacent indications and assets over time.
Current Focus
Aedion holds global exclusive rights and supply to VMD55 — establishing the legal and commercial foundation from which the development programme advances. Current activities are focused on product standardisation and preparing for the Phase 2a clinical stage.
The current raise is directed at completing these foundational steps and funding the next clinical milestone. Full detail on the use of proceeds, development plan, and capital requirements is available in the Data Room under NDA.
Full capital requirements, use of proceeds, and development timeline are disclosed under NDA. Contact contact@aediontx.com to initiate the process.
Detailed due diligence materials — including regulatory strategy, IP documentation, and clinical planning — are available in the Aedion Data Room.